Therapeutics
Search By Attributes
Search Results
Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
---|---|---|---|---|---|---|
ACU193 | ACU-193 | Alzheimer's Disease (Phase 1) | Acumen Pharmaceuticals, Inc. | Amyloid-Related | Immunotherapy (passive) | |
AL044 | Alzheimer's Disease (Phase 1) | Alector | Inflammation | Immunotherapy (passive) | ||
AL101 | GSK-4527226 | Alzheimer's Disease (Phase 1) | Alector | Other | Immunotherapy (passive) | |
APNmAb005 | RAA7 | Alzheimer's Disease (Phase 1) | Aprinoia Therapeutics | Tau | Immunotherapy (passive) | |
BMS-986446 | PRX005 | Alzheimer's Disease (Phase 1) | Bristol-Myers Squibb, Prothena | Tau | Immunotherapy (passive) | |
IBC-Ab002 | Alzheimer's Disease (Phase 1) | ImmunoBrain Checkpoint | Amyloid-Related, Inflammation, Other | Immunotherapy (passive) | ||
Lu AF87908 | hC10.2 | Alzheimer's Disease (Phase 1) | Lundbeck | Tau | Immunotherapy (passive) | |
MEDI1814 | Alzheimer's Disease (Phase 1) | AstraZeneca, Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | ||
MK-2214 | Alzheimer's Disease (Phase 1) | Merck | Tau | Immunotherapy (passive) | ||
PNT001 | Alzheimer's Disease (Phase 1), Traumatic Brain Injury (Phase 1) | Pinteon Therapeutics | Tau | Immunotherapy (passive) | ||
PRX012 | Alzheimer's Disease (Phase 1) | Prothena | Amyloid-Related | Immunotherapy (passive) | ||
TB006 | Alzheimer's Disease (Phase 1) | TrueBinding, Inc. | Inflammation | Immunotherapy (passive) | ||
Trontinemab | RO7126209, RG6102 , Brain shuttle gantenerumab |
Alzheimer's Disease (Phase 1) | Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) |